Crinetics Pharmaceuticals Inc (CRNX) - Total Liabilities
Based on the latest financial reports, Crinetics Pharmaceuticals Inc (CRNX) has total liabilities worth $120.68 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Crinetics Pharmaceuticals Inc - Total Liabilities Trend (2016–2025)
This chart illustrates how Crinetics Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Crinetics Pharmaceuticals Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Crinetics Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Crinetics Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yifeng Pharmacy
SHG:603939
|
China | CN¥14.41 Billion |
|
Luxi Chemical Group Co Ltd
SHE:000830
|
China | CN¥16.76 Billion |
|
Cohen & Steers Inc
NYSE:CNS
|
USA | $187.76 Million |
|
VALLOUREC ADR 1/5/EO 2
F:VACE
|
Germany | €2.49 Billion |
|
Beta Technologies, Inc.
NYSE:BETA
|
USA | $287.85 Million |
|
Independent Bank
NASDAQ:INDB
|
USA | $21.24 Billion |
|
Shihlin Electric & Engineering Corp
TW:1503
|
Taiwan | NT$20.40 Billion |
|
Shenzhen Sed Industry Co Ltd
SHE:000032
|
China | CN¥60.02 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Crinetics Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CRNX market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crinetics Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crinetics Pharmaceuticals Inc (2016–2025)
The table below shows the annual total liabilities of Crinetics Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $143.41 Million | +30.63% |
| 2024-12-31 | $109.79 Million | +14.07% |
| 2023-12-31 | $96.25 Million | +168.49% |
| 2022-12-31 | $35.85 Million | +87.97% |
| 2021-12-31 | $19.07 Million | +31.29% |
| 2020-12-31 | $14.53 Million | +9.73% |
| 2019-12-31 | $13.24 Million | +18.30% |
| 2018-12-31 | $11.19 Million | -63.46% |
| 2017-12-31 | $30.62 Million | +62.85% |
| 2016-12-31 | $18.80 Million | -- |
About Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acrome… Read more